Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75

Benzinga · 1d ago
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.